Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RGC Is Developing A Breakthrough Approach To ADHD And ASD
Traditional “western” medicine has made amazing advances and is one of the great innovations in history, but, unfortunately, there are still many conditions afflicting people that western medicine hasn’t been able to treat with any great effectiveness. It’s in instances like these that it can be beneficial to look to a medical approach that’s been around for over 2,000 years—a practice known as Traditional Chinese Medicine (TCM). It’s this approach that Regencell (NASDAQ:RGC) is embracing to improve the lives of the millions dealing with Attention Deficit Hyperactive Disorder (ADHD) and Autism Spectrum Disease (ASD) and an approach that has shown some encouraging improvements that sufferers of these conditions and their families are likely to be interested in.
The market that Regencell is attempting to address is even larger as they are likely to enter the Chinese and Hong Kong markets as well. One interesting difference to pay attention to as Regencell moves forward is that a treatment such as this can enter the US market as a nutritional product and therefore requires no governmental approval, reducing the barriers to entry in the US. In China and Hong Kong, however, a Proprietary Chinese Medicine (PCM) designation is needed for the product to be sold, a situation the company is well versed in and will pursue as the treatment gets closer to being ready for commercialization.
The company just completed the second efficacy trial, which was designed to evaluate and assess the effectiveness of Regencell’s standardized TCM formula in reducing ADHD and ASD symptoms during the course of a 3-month treatment. The trial is a non-blinded efficacy trial and patients in the trial were between 6 and 12 at the time of the treatment and clinically diagnosed with ADHD and/or ASD. The program required all patients to stop their existing medications, attend weekly treatment sessions with their parents, and follow the TCM Practitioner’s dietary guidelines during the 3-month treatment. Regencell selected 7 children (6 males and 1 female) to participate in the trial. 3 of the patients were diagnosed with ADHD and 4 of them with ASD.
The first results from this trial were just released and showed encouraging improvements. When dealing with these conditions, the company used three different methods to measure improvement:
• SKATBT-A3—48-item questionnaire designed and developed by Regencell to evaluate the effectiveness of a treatment in improving ADHD and ASD patients’ symptoms. SKATBT-A3 assesses a patient’s overall physical and neurodevelopmental conditions. SKATBT-A3 includes elements that are conditions of patients usually observed during TCM treatments such as: (i) speech/language/communication; (ii) patients’ sociability; (iii) sensory/cognitive awareness; and (iv) physical health and behavior.
• VADRS—a tool commonly used to measure ADHD severity.
• ATEC—The ATEC was designed as a comparative subscale for ASD diagnosed individuals – that is to measure change in ASD individuals due to various interventions by difference between the initial (baseline) ATEC scores and later ATEC scores.
All patients orally consumed the standardized TCM formula twice daily for 3 months. Improvements in patients’ symptoms were assessed weekly during treatment review sessions with the TCM Practitioner and the children’s parents.
And here’s the exciting part, after three months, the SKATBT-A3 scores of all patients were lower, indicating fewer problems and improvements in symptoms. According to the company, there were noticeable improvements in the patients’ overall health, ADHD symptoms and ASD symptoms. Common improvements noted included better sleep quality, reduced temper, better bowel movement and healthier complexion. The most notable improvement was demonstrated by two patients who gained the ability to control their tongues naturally without the aid of their own hands after the 3-month treatment. According to company management, this development is noteworthy because limited tongue function affects verbal communications and language abilities.
Improvement was also seen in the measures not designed by Regencell, with the VADRS scores of five patients coming in lower, indicating fewer problems and improvements in symptoms, while one patient’s score remained the same and one patient’s score was higher. Percentage improvements of patients ranged between -21% and 62%, with a mean of 21%. Additionally, the ATEC scores of all patients were lower, indicating fewer problems and improvements in symptoms. Percentage improvement of all patients ranged between 4% and 52%, with a mean of 22%. The company provided some color on the ATEC results and noted that they saw the most significant drop in scores in the health/physical/behavior subscale. Constipation, sleeping problems, poor appetite, anxiety/fearfulness, and irritability are common issues among ADHD and ASD patients and according to Regencell most of the patients suffered from these symptoms before the treatment but these symptoms improved after the treatment.
Importantly, none of the patients experienced any adverse side effects after the 3-month treatment. Additionally, while no guarantees can be made, herbal TCM treatments have an accumulating effect, meaning that while the greatest gains may be seen during the initial months of treatment, progress can be expected to continue the longer treatment is maintained.
While these are trials and there are no conclusions yet, the results seen so far warrant attention and we recommend investors to continue to monitor Regencell’s updates and developments. We are excited for the potential impact and market opportunity of the treatment.
https://scr.zacks.com/news/news-details/2022/RGC-Forging-a-New-Approach-to-ADHD-and-ASD/default.aspx
RGC's own foundation and efforts to treating ADHD, ASD and Alzheimers
Founded in 2017, the Regencell Foundation is a nonprofit organization dedicated to providing assistance to children with ADHD and ASD, and elderly people with dementia, particularly those who are facing financial difficulties.
ADHD and ASD is a neurodevelopmental disorder characterized by impaired social interaction, challenges in verbal and non-verbal communication, and restricted and repetitive behavior. There are more than 383 million people diagnosed with ADHD and ASD globally. The foundation aims to improve the lives of children during their critical stages of development and to help them become independent to lead a normal life.
Alzheimer’s disease, the most common form of dementia, is a growing public health crisis. According to Alzheimer’s Disease International, 46.8 million people worldwide were living with dementia in 2015 and that number is expected to double every 20 years. Our mission is to reduce the burden on caregivers and their families and allow the elderly to live life with dignity.
We have supported and sponsored many charitable organizations in the past and will continue to do so in the future. For example, we have partnered with Community CareAge Foundation (CCAF) to provide dementia assessment and diagnosis, as well as financial aid.
More recently during the COVID outbreak in 2020, we have been donating masks, grocery vouchers, and hand sanitizers to The Neighborhood Advice Action Council (NAAC), a non-profit organization which lends a hand in the densely populated and deprived districts to provide consultation and counselling services to residents of all sectors.
Regencell Foundation is established by Regencell Bioscience Holding ($RGC) which is a small cap stock listed on the Nasdaq Market last year 2021. The company was founded by Mr Au Yat-Gai, whom is CEO and also a practicing Traditional Chinese Medicine practitioner himself.
Aside from works performed by the Regencell Foundation, the owner of RGC, Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
https://www.regencellbioscience.com/regencell-foundation/
$RGC CEO, Mr Yat-Gai Au said he agreed with $TSLA CEO Elon Musk that sophisticated hedge funds are using short-selling and complex derivatives to take advantage of small investors.
“I will continue to draw a $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserve share options for all employees except myself,” Mr. Au said.
He pledged to continue to use his funds to purchase company shares to demonstrate his commitment to Regencell and his position against short and distort sellers.
With a total cumulative short volume of over 19 million shares since the company’s initial public offering (IPO), Mr. Au says he began his share purchases last year using his personal funds to further the company’s goal to save and improve lives.
Additionally, company directors and employees who were previously granted stock options upon the company’s IPO have agreed to a further lockup undertaking for six months after their stock options become vested.
Since Regencell's incorporation in October 2014 up to the IPO, Mr. Au has fully funded the company. Upon the IPO, his $3.25 million loan to the company was converted into approximately 342,000 common shares at an initial offering price of $9.50.
As we are going through an unprecedented time, people are trying to find innovative ways to reshape the world in a positive way. Mr. Au and Regencell have been practicing good corporate social responsibility (CSR) and are working towards an ESG framework by integrating its business and employees’ personal values to create a sustainable business for the future.
Mr. Au's and the company's philanthropic endeavors have not gone unnoticed. His idea is simple: perseverance to do social good and surround yourself with like-minded individuals will inevitably create a successful company, and that starts with hiring the best people who contribute to society and share the same values, where their actions count and views matter.
https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
Penny Stocks Of Companies Working On Long Covid
There are a number of small companies are working on long Covid treatments.
More than four in survey of 10 people said that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer.
Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems (https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html) that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
But so far, large companies are shying away from treating the condition.
Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disorders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s holistic approach toward the treatment process while preparing the TCM formulae for its patients.
(https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/)
Success of Regencell Bioscience #RGC and the man at the helm
Mr. Yat-Gai Au is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.
Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Havemeier, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.
Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.
He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.
Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.
As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors.
From offering grants to over 10,000 children with ADHD, ASD, and COVID-19 to establishing a company dedicated to saving and improving lives, this CEO may be taking philanthropy to a new level.
Over the years, Mr. Au says he has witnessed patients recover from attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) through TCM treatments. He wondered why such beneficial treatments are only available to a small number of patients and believed that the formula should be more readily available in order to help people around the world.
He established Regencell in 2014 after seeing notable improvements in many cases, including close friends and family members who had shown ADHD and ASD symptoms.
Giving Back
Regencell CEO says he is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged. In 2017, he established Regencell Foundation to be able to give back to society. He was taught at an early age that giving back is one of the most fulfilling thing one can do to make the world a better place.
In 2020, during the early-days of the COVID-19 outbreak when face mask were scarce, he sourced and donated over 200,000 masks to hospitals, the elderly and needy families in Korea, Singapore, Vietnam, Malaysia, Hong Kong and the U.S.
Mr. Au also disclosed that he is spearheading a philanthropic project to provide grants to over 10,000 children afflicted with ADHD, ASD, COVID-19 and those in severe financial distress.
“I started providing grants on April 16, 2022, and have already helped over 200 children,” he said.
https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
GME's Twin Brother Squeeze Play
Fellow redditors of r/wallstreetbets took Wall Street by storm when they rally against hedge funds and showing the high and mighty folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankruptcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
More so, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggressive or awarded traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Who Is Yat-Gai Au?
After graduating with a bachelor’s degree from the University of California, Berkeley’s Haas School of Business, Mr. Au began his career in investment banking at Deutsche Bank AG and ING Barings.
He has completed deals valued at more than $4 billion and won many prestigious merger and acquisitions (M&A) awards, according to reports.
Notable deals include the $750 million acquisition of Philippine Long Distance Telephone — now PLDT Inc. ADR , the $650 million acquisition of Indofood and the $1.8 billion secondary placement for 40% interest in Hagemeyer — all executed on behalf of First Pacific Company Limited (HKG: 0142).
https://www.benzinga.com/general/biotech/22/11/29658800/from-providing-grants-to-over-10-000-children-with-adhd-asd-and-covid-19-to-building-a-company-to
Traditionally Treating ADHD, ASD & COV19 via Traditional Chinese Medicine (”TCM”) - Small Cap Stock
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC’s Company Ownership average stock price
Understanding and looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders.
A high insider ownership often makes company leadership more mindful of shareholder interests. Small Cap stock, **Regencell Bioscience Holdings** (RGC) insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. (A positive indication)
We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Regencell Bioscience Holdings.
This counter is worth to put on your watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Regencell Bioscience Holdings.
Yat-Gai Au, Founder of the company, who spent a stonking US$1.2m on stock at an average price of US$25.23.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Yat-Gai Au purchased 68.34k shares over the year. The average price per share was US$26.03.
Defensive Strategy for Downtrend Market
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
$RGC EZPZ Squeeze Stock like GME!
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience healthcare company that focuses on heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
$RGC CEO Letter to Shareholders
Dear Shareholders:
As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyond.
For those who are new to Regencell, the Company focuses on the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”).
We have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. We aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. We are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
**Research Studies**
Our first study using personalized TCM formula in Hong Kong showed a drop in assessment scores meaning that ADHD and ASD symptoms were less severe for patient who participated in the study. However, there is no assurance that we can expect similar outcome in our second research study.
Encouraged by this positive outcome, we plan to commence our second research study next month in Hong Kong, which is expected to last for approximately one year. Approximately 100 patients will participate in our second research study, in 3-12 months treatment cycles. Our goal for the second research study is to verify the effectiveness of the standardized TCM formulae with candidates that are experiencing mild, moderate and severe ADHD and ASD conditions. Once completed, the research study will provide the foundation for the Company to apply for a proprietary Chinese medicine (“pCm”) registration in Hong Kong. We look forward to sharing the outcome as soon as we complete the study.
During a short period of time, we have achieved significant milestones, and these could not have been achieved without the tremendous backing of our long-time supporters. Speaking on behalf of our entire management team and board of directors, I would like to extend my thanks and deepest gratitude to:
**Mr. Samuel Chen and Mrs. Fiona Chen, Dr. Hai Ping Jin and Mr. Jay Lee** for their contribution and support to our research. Their investment gives hope to ADHD and ASD patients, their families and caregivers in need of a solution.
Also, **Mr. Sik-Kee Au**, our strategic TCM research partner, for offering his 30+ years of experience in TCM research & development, and clinical practice. Our partnership with Mr. Au has been instrumental in conducting our studies and has given us the exclusive rights and ownership of all his TCM formulae and the intellectual property rights of the TCM formulae.
Last but not least, I would like to thank all of our business partners, professionals and investors for making this possible, and to our team for the amazing work they continue to do every day.
[https://www.businesswire.com/news/home/20210805005564/en/Regencell-Bioscience-Holdings-Limited-Releases-CEO-Letter-to-Shareholders]
$RGC, a Short Squeeze potential like $GME
Fellow Redditors of Wallstreetbets took Wall Street by storm when they rally against hedge funds and showing the high and mighty folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankruptcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
More so, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggressive or awarded traders could keep in their watchlist.
https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i
$RGC Healthcare Company holding against Bearish Market
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO and had seen fallen victim to short sellers and hedge funds which took the shares down. Recently the share price has rose over 30% . The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$RGC Company Founder Buying Back Shares to Stop Short Sellers
CEO of Regencell Bioscience Holdings has voiced out against traders who are shorting and putting out negative schemes on the company stock, negatively impacting the company’s image.
Regencell Bioscience Holdings (RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
These negative schemes have indirectly put harm to RGC investors and patients whom rely on the company’s developments to develop a natural approach towards treatment of Attention Hyperactive Disorder (ADHD) Autism Spectrum Disorder (ASD) and Covid-19.
RGC’s CEO (Mr Yat-Gai Au) has agreed to continue to only draw 1$ annual salary and with no bonuses until the company has reached $1 Billion market cap and reserve share options for all employees except himself. He has even pledged to continue putting personal funds to buyback company shares to display his commitment to the company and his stances against short sellers.
More so, to further demonstrate the company’s commitment, all directors and employees who were granted with stock options during IPO have agreed to a 6 months lockup after it is vested. These stocks options will be vested on July 16th 2022, hence it will remain locked until January 16th 2023.
https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo
$RGC Defensive Play in Action and its Rising Stock Price
Investors who wishes to diversify their portfolio should look into defensive stocks ie. Healthcare, F&B and Utility as a defensive play towards current market volatility. Regencell Bioscience Holdings (RGC) is a healthcare company.
The company has seen a heavily beatdown during early months of Q2 of 2022, but is currently seeing a positive movement in the market price. Recently, the stock has seen a stellar rise of 30%.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
Regencell Bioscience - a Traditional Chinese Medicine Company and Philanthropist CEO
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
The CEO's Conviction $RGC
Regencell Bioscience Holdings (RGC), a healthcare bioscience company, has been a topic of trend amongst traders and short sellers, who have seen its price take a beating a few months after its IPO last year.
The CEO (Mr. Au) has voiced his concerns that these negative sentiments are not only hurting the company but also investors and patients who are seeking treatments.
RGC’s business model is focused on using Traditional Chinese Medicine (TCM) to treat attention hyperactivity disorder ("ADD"), autism spectrum disorder ("ASD"), and COVID-19-like illnesses, and these negative FUD (Fear, Uncertainty, and Doubt) are obstacles to the company’s mission and goal.
These negative sentiments are strategies deployed by sophisticated hedge funds by using short selling and complex derivatives to take advantage of small investors.
In defense against these strategic ploys by these hedge funds, Mr. Au has agreed to only draw $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserves share options for all employees except himself.
Furthermore, Mr. Au’s personal funds will be used to buyback company shares to demonstrate his commitment to the company and to reposition against short and distort sellers. Based on publicly available data, the company believes there is a total cumulative short volume of over 19 million shares since the company’s IPO.
Mr. Au "I began my share purchases last year, using my personal funds in order to further our goal of saving and improving lives."
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Healthcare Bioscience Company - Regencell $RGC holding against raging markets
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO was consolidating between $20-$22 before its resistance breakout in May 22” and shown a bullish pattern in recent weeks. The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
Looking into $RGC Regencell Bioscience. Company with strong management.
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medicine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
More so, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
TCM treatment for Covid19 Patient - Regencell Bioscience $RGC
Regencell Bioscience’s Traditional Chinese Medicine (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the company’s positive progress in medical, the CEO (Mr Yat-Gai au) has shown his confidence in the progress of the company direction and has yet to sold a single share since taking the company IPO. Mr Yat has also pledged to refrain from taking salary and bonus (<1$) until the company reaches US$1 Billion market cap.
https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html
$RGC CEO Buying Back Shares at average price of USD $26
The company CEO of Regencell Bioscience Holding (RGC) has been buying back shares over the year. (over 68.34k shares with average price of $USD26) which is not far from last night’s closing price at $USD$27.50 .
In fact, the company CEO (Mr Au) ‘s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html
$RGC: Regencell Bioscience - Defensive Stance in Downtrend Market
The past months of market volatility has not been kind to many tech and growth sector stocks which has seen large drops between 30-50%. The recent beatdown of these sectors are mainly due to the market uncertainty of growing inflation numbers, quantitative easing of Fed's reserve, Russian-Ukraine War and rise in oil pricing.
The market has diverted its attention from the growth sector and into defensive sectors ie. healthcare, utilities and consumer staple; which are less volatile and less sensitive to the economic cycle. The simple understanding is that these sectors fall under human essential services, necessary for any day to day affair.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The company's CEO (Mr. Yat-Gai Au), since IPO day has bought over $5 million of ordinary shares and has not sold any shares despite the having seen the stock price rose staggeringly. The company is currently in the business for the long run and will continue to be vested in its business model of developing treatments for AHDH and ASD as treatment trials are ongoing.
https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
$RGC is a potential hidden healthcare company
The Forbes mags' shares the below advantages of holding a healthcare "Defensive" Company Share.
"1. As defensive stocks, healthcare companies provide steady returns in any market. Because people will always need healthcare, the healthcare sector provides very steady, consistent returns that are uncorrelated with the overall direction of the stock market.
2. The U.S. healthcare sector is growing faster than the rest of the economy. Growth in the sector is being propelled by technological advances, an aging population and improving treatments for chronic diseases and conditions.
3. Healthcare spending in the U.S. is seeing strong, sustained growth. National health spending is projected to grow at an average annual rate of 5.4% through 2028, reaching $6.2 trillion and 19.7% of the country’s GDP."
Aside from having a favorable position as a "defensive" healthcare company, RGC's management and CEO has taken a more transparent approach to the company's investors.
- Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx
“Fed will push us into recession”
Economists have been raising their doubts in the FED’s capability in handling the rising inflation rate which is looking to fall of the edge into a oblivion recession.
As shared by economist Mohamed A. El-Erian “It is, unfortunately, uncomfortably possible that the Fed is going to slam on the brakes and push us into recession,” during his interview on Yahoo Finance Live in an online interview.
El-Erian’s also remarks that the Fed’s move last week in raising interest rates by 75 basis points (the most aggressive hike in decades) has made Wall Street strategist in notion for an economic slowdown.
The US Central bank was too late in acknowledging that inflation will become a problem and was not quick enough to reacting to the surging prices thus losing credibility in the eyes of wall street and also investors.
Losing credibility in the FED will lead to people doubting its projects, consequently leaving the people with skepticism and distrust towards the FED.
[https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html](https://finance.yahoo.com/news/its-uncomfortably-possible-fed-may-push-us-into-recession-economist-164054602.html)
Investors are suggested to rotate their portfolio into defensive sectors which are known to be resilient towards times of economic recession ie. Healthcare, F&B, Utilities and REITs.
Regencell Bioscience Holdings , ticker $RGC is a bioscience healthcare company which had been listed in the NASDAQ market in USA. The company’s business is predominantly in the Research & Development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease esp. COVID-19, for which there are unmet holistic medical needs in the global market.
Since its inception into IPO last year July, the stock has seen a 300% rise. The stock has a Outstanding Shares of 13.01M and Floating Shares of 1.44M. The CEO is currently holding >80% of the company shares.
RGC share buyback by Company CEO/Philanthropist
RGC a healthcare company which has been on the target of shortsellers in Q2 22’ is taking on the full might of the company CEO.
Based on the the CEO’s Schedule 13D fillings with the SEC (US Security and Exchange Commission), CEO (Mr Au) has used an aggregate of $5.03 mil of his personal funds to purchase ordinary shares on open market between July 2021 and May 2022. A total of 10,539,159 ordinary shares are now owned by the Mr Au, which represents approximately 81% of company’s total issued and outstanding ordinary shares.
The company’s mission is to develop a natural treatment method for neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19.
Aside from RGC’s approach in developing successful treatments for ADHD and ASD, Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
RGC: Another counter in eyes of Short Sellers. Short Squeezers to Arms!
Short sellers have their sights set on Regencell (Nasdaq: RGC).
After taking the company IPO last year on July 2021, RGC became a victim for short-sellers where intraday volume often as high as 40% - 90% are recorded on certain days. According to the SEC, this coordinated pattern could be an indication of a possible “naked short” which took place strategically.
In comparison of numbers, RGC’s total reported cumulative short volume is > 19 million shares while its total reported short volume to outstanding shares ratio (excluding CEO and Chairman ownership) is 7.63x. RGC is more heavily shorted than GME (in fact almost double)
Company with strong management
A company with strong financials is crucial. However, a company with strong leadership and management is equally as critical to the long term growth of a company.
When investors look for a company, the quantitative aspect is usually sought-after (ie. profit growth, cash flow, debt, etc) as the primary focus. However the qualitative (company leadership and management) nature of the company should also be taken into consideration. Qualitative assets are usually harder to detect as they are not quantifiable but numbers and figures.
Examples of successful companies with strong qualitative are like META (previously Facebook).
Meta grew as it holds appeal to the public and has been smart about acquiring businesses and recruiting/retaining talents. The CEO’s efforts (Mark Zuckerberg) also grin up near-term revenue prospects with its push into TV-like contents.
Presently, we take a look at a defensive healthcare company (RGC) Regencell Bioscience Ltd. A company focusing on using Traditional Chinese Medine to treat ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
Since listing, the company CEO has purchased over $5 MIL of ordinary shares and has yet to sold any as of today. This qualitative aspect of the company displays the company and managements confidence and conviction about the company’s direction and future.
Moreover, the CEO will continue to deployed personnel funds buying back shares all against the market shorters and sellers.
The company has a prominent investment backer, Samuel Chen, who had a significant position in ZOOM (8.8% holding) post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Investors should always remember to look into the qualitative face of the company, as it does play a part in identifying the strength of the company.
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
Mr Au, the company’s CEO and chairman has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.
Presently, the company’s business plan of expansion is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
&RGC Stock Price Movement
The Fed is hiking interest rates quickly in an attempt to calm rising inflation, which has affected many stock investors who are witnessing bleeding portfolios on their phones or PCs.
Companies are expected to cut profit forecasts in the coming quarter due to rising inflation rates and a potential decrease in earnings.
Investor Rick Rule told MoneyWise earlier this year, "I do not believe the broad equity market would take many rate rises."
The rule does not advocate selling all of one's holdings.
This takes us to a healthcare stock that had an IPO last year on July 22nd and had a terrific run of 300% capital gains after listing. Shares have taken a significant damage as a result of short sellers and hedge funds intentionally targeting the firm shares. RGC, on the other hand, has returned to the $30s, buoyed by positive research findings for Regencell's RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder contact, and market support for the shares.
The formulas proposed seek to treat the underlying causes of diseases while also easing symptoms and enhancing general health. RGC's TCM employs natural materials to treat diverse aspects in the body, and every physiological function is taken into account while formulating TCM formulations for patients.
Unlike other early-stage organisations, RGC has chosen a more open strategy that is well-aligned with shareholders' long-term interests.
Some highlights of the company's leaders and founders that demonstrate long-term commitment to the company:
- The CEO will get only a $1 yearly salary and no bonuses until the company's market valuation hits $1 billion.
- The CEO will continue to purchase back company shares to demonstrate his commitment to the firm and to strengthen its position against short and distort sellers.
- All directors and employees who were previously given stock options at the Company's IPO have agreed to a six-month lock-up following the vesting of their stock options. Because their stock options are slated to vest on July 16, 2022, their shares will be locked up until January 16, 2023.
RGC hopes to provide findings from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.
When the report is out, we will know if the firm has been making positive development on the company.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
An early Zoom investor was interested in another company #RGC.
Regencell Bioscience Limited (NASDAQ:RGC) is a bioscience and healthcare company that focuses heavily on R&D and commercialization of Traditional Chinese Medicine (TCM) treatment, specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), as well as infectious diseases affecting people's immune systems such as COVID.
The stock price has increased by more than 300 percent since its IPO and saw a significant sell-off in mid-June, although it has recovered roughly 40% from its lows in June.
Of course, one of the greatest and strongest supporters of the business share is none other than the company) who believes in a better and brighter future for the firm.
In support of his dedication, belief, and position in the firm, the founder and CEO, (Mr Yat-Gai Au), has committed approximately $5 million dollars of his own reserves in purchasing back company shares to posture against probable short and distort sellers.
Mr Samuel Chen, a highly successful early **Zoom Video Communications, Inc.** investor, is another famous early RGC investor (Nasdaq: Zoom). Mr Samuel was the second largest individual investor, owning 8.8% of Zoom shares.
Mr. Au has so far converted his shareholders' loan of $3.25 million to Regencell's ordinary shares upon listing, vowed not to take more than $1 in pay and bonus until Regencell reaches a $1 billion market capitalization, and reserved share options for all workers except himself.
Furthermore, to demonstrate management's commitment to the firm, all directors and employees who were previously awarded stock options at Regencell's IPO have committed to a six-month lock-up period once their stock options become vested. Their shares will be locked up until January 16, 2023, since their stock options are slated to vest on July 16, 2022.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Live on SSN Network on the effectiveness of TCM in treating COVID19 #RGC
Regencell Bioscience Limited is a Hong Kong-based firm that is pioneering the use of Traditional Chinese Medicine ("TCM") to cure not just ADHD and ASD, but also the Covid-19 virus, which shocked the globe in 2020.
RGC now offers a therapy formula that has been tested on 19 individuals (suspected or confirmed COVID cases). After an average of 5 days of therapy, 12 of 19 patients showed signs of progress in their recovery.
[https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html](https://finance.yahoo.com/news/regencell-describes-traditional-chinese-medicine-133000084.html)
Separately, while Mr Au, the business's CEO and chairman, was not present for the interview, he has been working behind the scenes to protect his company from recent short seller and trader attacks on the company's shares. Since the company's IPO, Mr Au has purchased nearly $5 million in stock.
"While research is still underway," Mr Au stated, "we are certain that our formula can make a difference in the fight against COVID-19."
Company CEO/Philanthropist buys back RGC shares
RGC, a healthcare business that was targeted by shortsellers in Q2 22', is facing the full force of the company CEO.
According to the CEO's Schedule 13D filings with the SEC (US Securities and Exchange Commission), the CEO (Mr Au) spent $5.03 million of his own cash to buy ordinary shares on the open market between July 2021 and May 2022. Mr Au currently owns a total of 10,539,159 ordinary shares, accounting for nearly 81% of the company's total issued and outstanding ordinary shares.
The company's objective is to provide a natural treatment technique for neurocognitive disorders and degenerations, notably ADHD and ASD, as well as viral illnesses that impair people's immune systems, such as COVID-19.
Aside from RGC's approach to developing successful treatments for ADHD and ASD, Mr Au has also been involved in his own philanthropic project (within his own means) that aims to provide care to over 10,000 affected children with ADHD, ASD, and Covid-19, as well as those affected by financial difficulties. Mr Au's programme has already benefitted over 150 youngsters since its inception on April 16, 22.
$RGC is defending itself against short sellers.
RGC has received a lot of short and unfavorable market commentary from sceptics. During this time, the company's CEO (Mr Au) has been purchasing back shares for $5 million.
Regencell Bioscience Holdings (RGC: Nasdaq) is a bioscience healthcare firm in the early stages that focuses on R&D and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
The firm has recently been on an upward trajectory, demonstrating its endurance in uncertain times, thanks to its main industry: healthcare.
Healthcare stocks, for example, have demonstrated through time that they are resistant to market volatility and are highly regarded by institutional investors and fund managers.
Despite being severely shorted in the early months of Q2 22', the firm stock has been on an upward trend despite the massive sell-off in several market sectors, particularly the growth stock and cryptocurrency markets.
$RGC is a possible undervalued healthcare firm.
The Forbes mags' shares the below advantages of holding a healthcare "Defensive" Company Share.
"1. As defensive stocks, healthcare companies provide steady returns in any market. Because people will always need healthcare, the healthcare sector provides very steady, consistent returns that are uncorrelated with the overall direction of the stock market.
2. The U.S. healthcare sector is growing faster than the rest of the economy. Growth in the sector is being propelled by technological advances, an aging population and improving treatments for chronic diseases and conditions.
3. Healthcare spending in the U.S. is seeing strong, sustained growth. National health spending is projected to grow at an average annual rate of 5.4% through 2028, reaching $6.2 trillion and 19.7% of the country’s GDP."
Aside from having a favourable position as a "defensive" healthcare company, RGC's management and CEO has taken a more transparent approach to the company's investors.
- Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
- Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
- Will not award share options for himself;
- Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx
The majority of 2021 IPOs failed. This is the prize winner
2021 was the busiest year for deals since 2000, with a record-breaking IPO rush of 1,035 listings in the US, with the biotech and healthcare sectors leading the way, accounting for 36% of all IPO activity.
While most investors are busy reviewing stocks in their current portfolio, it may come as a surprise which company came in first for stock return. Although it is currently not a household name, any savvy investor should keep this stock on their radar: Regencell Bioscience $RGC
RGC is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
A June 2022 article mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
RGC’s Solid Foundation
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
Comparison to 2022 IPO Top Performer
A recent stock that has gone to the moon since its mid-July 2022 IPO is AMTD Digital ,$HKD.
The controlling shareholder, AMTD Group Company Limited, was founded by billionaire Li Ka-shing’s CK Hutchison Holdings Limited in 2003. HKD’s IPO price was $7.80 and has gained over 9,000% since, closing at $ $30.42 on October 11, 2022.
https://www.benzinga.com/general/biotech/22/08/28316977/a-look-into-the-top-performing-ipo-stock-of-2021
Regencell CEO Yat-Gai Au has created an organization that is about more than profits -- it's about changing lives. His aim is to change the way patients are treated
Human genius grows from humble origins.
Yat-Gai Au developed Regencell Bioscience to help more people benefit from natural and holistic medicines, with the objective of ensuring that everyone has equitable access to such therapy for many years to come.
Several individuals have made significant contributions to RGC's overall performance during the previous few years. Dr. Chao (Chief Medical Officer) and James Chung (Chief Operating Officer), who joined Regencell in 2015 and 2019, respectively, were motivated by their own experiences with TCM and the significant improvements they saw in ADHD and ASD patients.
"For our organisation to remain loyal to what we believe in and continue to move in the correct path, we must surround ourselves with the appropriate individuals who share our values and interests. Our staff creates plans and supervises scientific testing to verify that our services and products are effective, safe, and beneficial "Yat-Gai concurs.
The organisation has evolved into more than merely a research and development institution for neurocognitive diseases and degenerations. "It is opening the path for exceptional advancements in TCM to become commonplace. Why should these ground-breaking therapies be limited to a restricted set of individuals or communities?"
The results of a recent clinical trial, the EARTH Trial, revealed that RGC-COV19TM is an effective solution for the relief and eradication of COVID-19 symptoms within 6 days. As a result, the chances of hospitalisation and mortality are reduced. TCM and traditional medicine have been demonstrated to be successful in a hyper-modern, tech-driven environment through rigorous experiments.
Keeping it intimate and close
Although RGC's clinical trials will still need to be peer-reviewed in the coming months, there is significant market interest because the firm has created a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that seeks to make a difference wherever feasible, and while our R&D may be confined to a few sectors of interest, we will be able to widen our perspectives to more complicated therapies over time," Yat-Gai quickly remarks.
Regencell received net funds of $22.7 million from its IPO, investments that aided the company's access to the tools and resources required to expedite clinical research.
Yat-Gai has found that after the company became public, short and distorting groups or people have begun to impact their stock price and mood. "Enterprises like ours are not given the opportunity to establish themselves because the offenders are pushing down the value of smaller companies, leading the market and general public to lose faith. This harms our firm, notably the patients, some of whom are yearning for a solution "he stated.
Yat-Gai was able to acquire over $5.9 million in regular firm shares to assist reduce the detrimental consequences of such short-term strategies. Yat-Gai Au currently holds an 81% ownership in the firm. Other owners possess around 19% of the remaining shares.
"To date, I have invested millions of dollars of my personal funds on RGC stock. My most recent acquisition was $886,000 in RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the firm and its future, and I aim to continue putting my money where my mouth is by increasing my shareholdings."
Because majority ownership is kept within the firm, often known as 'Insider Ownership,' it allows them to have greater influence over crucial decision-making concerns, which can assist accelerate the company's overall development goals.
"The decision to continually acquire RGC shares over the last several months is to support and ensure the company's promise may be realised for years to come. We've invested a lot of time, energy, and money in Regencell, and we're fully aware of the potential difference it can make in the area of alternative medicine. I feel that if I lead the way, our organisation will be able to reach the goals we've set for ourselves in the next years."
Long-term transactions not only provide the firm more control over important decision-making, but also allow them to increase investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337
As investors are on the lookout for cheap biotech stocks which may have great potential upside, the slow and steady performance of some companies may present viable financial returns in the coming years.
One company of interest in this specific category is Regencell Bioscience Holdings Limited (NASDAQ:RGC), an early-stage bioscience company focusing on the research, development, and commercialization of Traditional Chinese Medicine ("TCM").
Regencell Bioscience focuses on the research and development of neurocognitive disorders and degeneration, more specifically in ADHD, ASD, and infectious diseases such as COVID-19.
The bioscience company went public with around 2.6 million ordinary shares at $9.50 per share, raising approximately $22.7 million.
RGC has kept investors interested and has received media attention for all the right reasons; the most recent - the company's chairman and CEO, Yat-Gai Au used over $5.9 million of his personal funds to purchase ordinary RGC shares through the open market to support the growth and potential of the company.
Sizable stock purchases by insider investors, with the CEO being an exception, have helped the company sidestep short sellers and hedge fund managers that have been taking advantage of small-time investors. Currently, the company has just over 2.6 million shares on the market available for trade.
Why $RGC?
RGC is not ordinary, and in many ways, we can see why investors have started noticing the company.
So far, year-to-date share prices have increased by 17.03% while the Nasdaq Biotechnology Index has only gone up by 2.69%. On average, share prices are zig-zagging between $34.79 and $35.84, and some investors have set up their year range closer to $59.00 per share.
For the six months between July 2021 and December 2021, the company reported a basic diluted loss per share of $0.29, compared to $0.03 for the same period of 2020.
The loss could be attributed to the company's sudden increase in operating expenses, which jumped from $368,465 for the 6 months ending December 31, 2020, to $3,658,906 for the same period in 2021, an increase of roughly 893%.
The company reported cash availability of $19 million in December 2021, compared to $0.06 million in June 2021. The main source of cash came from net proceeds of the company's IPO, including proceeds from the sales of over-allotment shares, totaling approximately 22.7 million.
Initially, when the company went public back in July 2021, share prices were well below their current levels, and a month later, in August 2021, share prices jumped as much as 204% in a single trading session. Since going public, Regencell has treated more than 88 COVID patients with over 94% effectiveness in eliminating symptoms within 6 days; they have ongoing ADHD/ASD clinical studies and were included in the MSCI world microcap index. RGC was also one of the top best-performing stocks on Nasdaq in 2021, according to www.stockanalysis.com.
Late last year, Regencell entered preliminary trials for ADHD/ASD. During this time, the stock was trading in the low $20's range. By mid-February 2022, share prices had climbed over $40 before scaling down to the $20's range.
Although market conditions have been volatile and investor sentiment negative, RGC has performed quite well since April 2022, with share prices making a swing above $30. The recovery of the stock performance comes from positive clinical results related to the company's RGC-COV19 TCM formula.
From our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response.
The promising track record and positive clinical results have kept investors interested as RGC has remained relatively stable and resolute in its performance. For investors who can digest small purchases a lot better, RGC could outpace sluggish market conditions.
https://seekingalpha.com/article/4534812-slow-and-steady-wins-the-race-with-regencell-bioscience
About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.
Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.
On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.
Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.
Humble beginnings lead to human ingenuity
Yat-Gai Au founded Regencell Bioscience so that more people can benefit from natural and holistic treatments with a goal to provide everyone equal access to such treatment for many years to come.
Throughout the last few years, several people have largely contributed to the overall success of RGC. James Chung (Chief Operating Officer) and Dr. Chao (Chief Medical Officer), who joined Regencell in 2015 and 2019, respectively, were inspired by their personal experience with TCM and the major improvements they saw on ADHD and ASD patients.
"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.
The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"
In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.
Keeping it close and personal
Although the clinical studies completed by RGC will still need to be peer-reviewed in the coming months, there's been growing interest from the market as the company has built quite a reputation for its research and development (R&D) in the field of alternative medicine.
"We are a company that looks to make a difference where it's possible, and while our R&D may be limited to a few fields of interest, over time we'll be able to broaden our perspectives to more complex treatments," Yat-Gai briefly mentions.
Through its IPO, Regencell had net proceeds of $22.7. million, investments that helped grow the company's access to the tools and resources needed to fast-track clinical studies.
Since the company went public, Yat-Gai has noticed that short and distort organizations or individuals are starting to affect their stock price and sentiment. "Companies like ours are not given the opportunity to prove themselves since the culprits are driving down the value of smaller companies, causing the market and general public to lose its confidence. This causes damage to our company, particularly the patients, some who are desperate for a solution," he said.
To help mitigate the negative effects of such short-term schemes, Yat-Gai managed to purchase more than $5.9 million worth of ordinary company shares. To date, Yat-Gai Au is the majority shareholder, with an 81% stake in the company. This leaves around 19% of shares owned by other shareholders.
"To date, I have spent millions of my personal finances on purchasing RGC shares. My most recent purchase was worth $886,000 of RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the company and its future and intend to continue to put my money where my mouth is and increase my shareholdings."
Seeing as majority ownership is held within the company, oftentimes referred to as 'Insider Ownership,' it allows them to have better control over critical decision-making issues that can help fast-track the company's overall development goals.
"The decision to repeatedly purchase RGC shares over the last several months is to support and ensure the potential of the company can be met for years to come. We've vested a lot of time, energy, and resources in Regencell, and we're well aware of the potential difference it can make in the field of alternative medicine. I believe that as I lead the way our company will be able to meet the goals we've set out to achieve within the coming years."
The long-term transactions not only give the company better control over critical decision-making but enables them to boost investor sentiment.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337